219 related articles for article (PubMed ID: 18217973)
1. Paraneoplastic cerebellar degeneration in ovarian carcinoma: case report with review of immune modulation.
Bradley WH; Dottino PR; Rahaman J
Int J Gynecol Cancer; 2008; 18(6):1364-7. PubMed ID: 18217973
[TBL] [Abstract][Full Text] [Related]
2. Paraneoplastic cerebellar degeneration as the first evidence of malignancy: a case report.
Kumari VA; Gupta P; Srivastava MV; Kumar L; Kriplani A; Bhatla N
J Obstet Gynaecol Res; 2014 May; 40(5):1463-5. PubMed ID: 24689522
[TBL] [Abstract][Full Text] [Related]
3. Transcriptomic immune profiling of ovarian cancers in paraneoplastic cerebellar degeneration associated with anti-Yo antibodies.
Vialatte de Pémille C; Berzero G; Small M; Psimaras D; Giry M; Daniau M; Sanson M; Delattre JY; Honnorat J; Desestret V; Alentorn A
Br J Cancer; 2018 Jul; 119(1):105-113. PubMed ID: 29899393
[TBL] [Abstract][Full Text] [Related]
4. Neurologic improvement after high-dose intravenous immunoglobulin therapy in patients with paraneoplastic cerebellar degeneration associated with anti-Purkinje cell antibody.
Phuphanich S; Brock C
J Neurooncol; 2007 Jan; 81(1):67-9. PubMed ID: 16773214
[TBL] [Abstract][Full Text] [Related]
5. Paraneoplastic cerebellar degeneration as the first evidence of cancer: a case report.
Liu S; Tunkel R; Lachmann E; Nagler W
Arch Phys Med Rehabil; 2000 Jun; 81(6):834-6. PubMed ID: 10857534
[TBL] [Abstract][Full Text] [Related]
6. Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration.
Small M; Treilleux I; Couillault C; Pissaloux D; Picard G; Paindavoine S; Attignon V; Wang Q; Rogemond V; Lay S; Ray-Coquard I; Pfisterer J; Joly F; Du Bois A; Psimaras D; Bendriss-Vermare N; Caux C; Dubois B; Honnorat J; Desestret V
Acta Neuropathol; 2018 Apr; 135(4):569-579. PubMed ID: 29299667
[TBL] [Abstract][Full Text] [Related]
7. Paraneoplastic Cerebellar Degeneration (PCD) associated with PCA-1 antibodies in established cancer patients.
Lehner MJ; Gheeya JS; Siddiqui BA; Tummala S
J Neurooncol; 2021 Jul; 153(3):441-446. PubMed ID: 34076832
[TBL] [Abstract][Full Text] [Related]
8. [Paraneoplastic cerebellar degeneration associated with ovarian cancer: anti-Yo immunoreactivity in autoptic cerebellum and ovarian carcinoma].
Bartos A; Stourac P; Rusina R; Sejdová M; Velenská Z
Nervenarzt; 2002 Oct; 73(10):995-8. PubMed ID: 12376889
[TBL] [Abstract][Full Text] [Related]
9. [Importance of plasmapheresis in the treatment of paraneoplastic cerebellar degeneration].
Basić-Jukić N; Kes P; Basić-Kes V; Brunetta B
Acta Med Croatica; 2004; 58(1):63-6. PubMed ID: 15125396
[TBL] [Abstract][Full Text] [Related]
10. Paraneoplastic cerebellar degeneration mimicking development of secondary progressive multiple sclerosis in a patient with relapsing-remitting multiple sclerosis.
Gracien R; Kordulla M; Ziemann U
Mult Scler; 2011 Apr; 17(4):498-500. PubMed ID: 21148018
[TBL] [Abstract][Full Text] [Related]
11. Paraneoplastic cerebellar degeneration associated with serous adenocarcinoma of the ovary.
Saeed DB; Gupta L
BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25432905
[TBL] [Abstract][Full Text] [Related]
12. Anti-Yo positive and late-onset paraneoplastic cerebellar degeneration associated with ovarian carcinoma: A case report.
Cui D; Xu L; Li WY; Qian WD
Medicine (Baltimore); 2017 Aug; 96(32):e7362. PubMed ID: 28796031
[TBL] [Abstract][Full Text] [Related]
13. Paraneoplastic cerebellar degeneration caused by ovarian clear-cell carcinoma.
Negishi Y; Sakai K; Noguchi Y; Iwasaki N; Kawai N
J Obstet Gynaecol Res; 2014 Feb; 40(2):614-7. PubMed ID: 24148073
[TBL] [Abstract][Full Text] [Related]
14. Immunological Bases of Paraneoplastic Cerebellar Degeneration and Therapeutic Implications.
Yshii L; Bost C; Liblau R
Front Immunol; 2020; 11():991. PubMed ID: 32655545
[TBL] [Abstract][Full Text] [Related]
15. Morphological and immunohistochemical characterization of paraneoplastic cerebellar degeneration associated with Yo antibodies.
Storstein A; Krossnes BK; Vedeler CA
Acta Neurol Scand; 2009 Jul; 120(1):64-7. PubMed ID: 19486326
[TBL] [Abstract][Full Text] [Related]
16. Isolated ZIC4 antibodies in paraneoplastic cerebellar syndrome with an underlying ovarian tumor.
Kerasnoudis A; Rockhoff M; Federlein J; Gold R; Krogias C
Arch Neurol; 2011 Aug; 68(8):1073. PubMed ID: 21825246
[TBL] [Abstract][Full Text] [Related]
17. Rapid Eye Movement Sleep Behavior Disorder in Paraneoplastic Cerebellar Degeneration: Improvement with Immunotherapy.
Vale TC; Fernandes do Prado LB; do Prado GF; Povoas Barsottini OG; Pedroso JL
Sleep; 2016 Jan; 39(1):117-20. PubMed ID: 26414894
[TBL] [Abstract][Full Text] [Related]
18. CDR2L Antibodies: A New Player in Paraneoplastic Cerebellar Degeneration.
Eichler TW; Totland C; Haugen M; Qvale TH; Mazengia K; Storstein A; Haukanes BI; Vedeler CA
PLoS One; 2013; 8(6):e66002. PubMed ID: 23823982
[TBL] [Abstract][Full Text] [Related]
19. Deterioration of anti-Yo-associated paraneoplastic cerebellar degeneration.
Finsterer J; Voigtländer T; Grisold W
J Neurol Sci; 2011 Sep; 308(1-2):139-41. PubMed ID: 21762925
[TBL] [Abstract][Full Text] [Related]
20. A case report of plasmapheresis treatment in a patient with paraneoplastic cerebellar degeneration and high anti-yo antibody titers.
Landtblom AM; Lindvall B; Ledin T; Berlin G
Ther Apher Dial; 2008 Feb; 12(1):82-5. PubMed ID: 18257818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
